China Taking Regulatory Route To Tighten Oversight Of Health Care Sector
This article was originally published in The Tan Sheet
China aims to upgrade supervision of its entire health care sector with an array of regulatory changes for pharmaceuticals and medical devices likely this year, including good manufacturing practice guidelines, according to a leading lawyer in the area of China's life sciences-related issues and legislation
You may also be interested in...
China's over-the-counter drug market grew more than 30 percent from 2007 to 2009 to more than RMB 90 billion ($13 billion), according to health care market intelligence provider IMS Health
China's State FDA insists it will align the country's pharmaceutical and medical device regulations with international standards. The question manufacturers have is, how soon
China's latest draft guideline on good manufacturing practices for drugs offers clarity on a few key points but still leaves huge gaps that need to be filled